Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

doi:10.1186/1475-9292-6-3

Kinetoplastid Biology and Disease

Volume 6

Viewing options:

Abstract
Full text
PDF (2.4MB)
Additional files

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Modabber F
Buffet PA
Torreele E
Milon G
Croft SL

on PubMed

Modabber F
Buffet PA
Torreele E
Milon G
Croft SL
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

Farrokh Modabber¹^,2, Pierre A Buffet³, Els Torreele¹, Geneviéve Milon⁴ and Simon L Croft¹

¹Drugs for Neglected Diseases Initiative (DNDi), 1 Place St Gervais, Geneva CH 1201, Switzerland

²Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, 79 Taleghani Avenue, Tehran 14166, Iran

³Centre Médical de l'Institut Pasteur, 28 rue du Docteur Roux, Cedex 15, Paris 75724, France

⁴Dept Parasitology and Mycology, Institut Pasteur, 25 Rue du Docteur Roux, Cedex 15, Paris 75724, France

Kinetoplastid Biology and Disease 2007, 6:3doi:10.1186/1475-9292-6-3


Published:	24 April 2007

Additional files

Additional File 1:

Product Profile for CL treatment. What characteristics should an ideal product have for treatment of CL and what is the minimum requirement for a product to be introduced for control of CL, with emphasis first on ACL and secondly of CL latin America caused by L. braziliensis.

Format: XLS Size: 37KB Download file

This file can be viewed with: Microsoft Excel Viewer